- Conditions
- Tobacco Use Disorder, Tobacco Dependence
- Interventions
- Quitbuddy, Control, SDoH Augmentation, SDoH Control
- Other
- Lead sponsor
- Bryan W. Heckman
- Other
- Eligibility
- 21 Years and older
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 143
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- Risperidone, Olanzapine (enrollment closed in this treatment), Molindone
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 8 Years to 19 Years
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 4
- States / cities
- Medford, Massachusetts • Chapel Hill, North Carolina • Cleveland, Ohio + 1 more
- Conditions
- Sickle Cell Anemia, Sickle Cell Disease, Hemoglobin Disorder
- Interventions
- Metformin, Questionnaires
- Drug · Behavioral
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 2
- States / cities
- Houston, Texas
- Conditions
- Great Saphenous Vein (GSV) With Venous Reflux Disease
- Interventions
- VenaSeal SCS, ClosureFast Radiofrequency Ablation (RFA), Roll-In (VenaSeal SCS)
- Device
- Lead sponsor
- Medtronic Endovascular
- Industry
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • San Diego, California • Greenwood Village, Colorado + 6 more
- Conditions
- Laser Therapy, Post Thoracotomy Pain
- Interventions
- AvicennaTM class IV laser application
- Device
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 25 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Childhood Solid Tumors
- Interventions
- Talazoparib, Irinotecan, Temozolomide, Filgrastim, Peg-filgrastim
- Drug
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- 12 Months to 25 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Myocardial Ischemia, Critical Illness, Endothelial Dysfunction
- Interventions
- Day Light, Placebo light, ICU Intense Light, ICU Placebo light
- Device
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
- Interventions
- Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib, Utomilumab, Liposomal Doxorubicin, Sacituzumab Govitecan
- Biological · Drug
- Lead sponsor
- Laura Huppert, MD, BA
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 12
- States / cities
- Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells
- Drug · Biological
- Lead sponsor
- C. Babis Andreadis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Various Advanced Cancer
- Interventions
- Nivolumab, Ipilimumab, Relatlimab, Daratumumab
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 578 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 14
- States / cities
- Tampa, Florida • Atlanta, Georgia • Lutherville, Maryland + 9 more
- Conditions
- Non-Small-Cell Lung Carcinoma
- Interventions
- Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin
- Biological · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 18
- States / cities
- Long Beach, California • Los Angeles, California • Orange, California + 12 more
- Conditions
- Renal Cell Carcinoma
- Interventions
- Atezolizumab, Bevacizumab, RO6874281
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 3
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Baltimore, Maryland
- Conditions
- Oncology
- Interventions
- BAY94-9343, BAY94-9343 (Expansion), BAY94-9343 (1.8 mg/kg), BAY94-9343 (2.2 mg/kg)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 8
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Bethesda, Maryland + 5 more
- Conditions
- Lymphoma
- Interventions
- Parsaclisib
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Tempe, Arizona • Redondo Beach, California + 27 more
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Esophageal Adenocarcinoma
- Interventions
- Nivolumab, Ipilimumab, Oxaliplatin, Capecitabine, Leucovorin, Fluorouracil
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,031 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 27
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 21 more
- Conditions
- Knee Osteoarthritis
- Interventions
- Duloxetine, Intra-Articular Injection, Nerve Procedure with long acting blocks, Nerve Procedure with nerve ablation, Pain Coping Skills Training, Best Practices
- Drug · Combination Product · Procedure + 2 more
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,937 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 24
- States / cities
- Sacramento, California • San Diego, California • Aurora, Colorado + 19 more
- Conditions
- Advanced Solid Tumor, Malignant Solid Tumor
- Interventions
- Ifinatamab deruxtecan (I-DXd)
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 247 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 10
- States / cities
- Denver, Colorado • Sarasota, Florida • Boston, Massachusetts + 6 more
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma
- Interventions
- BOLD-100 +/- FOLFOX Chemotherapy (Arm VII), BOLD-100 in combination with FOLFOX Chemotherapy (Arms I-VI)
- Drug
- Lead sponsor
- Bold Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 220 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Santa Monica, California • Tampa, Florida
- Conditions
- Cancer
- Interventions
- CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab, CGC-11047 and erlotinib, CGC-11047 and cisplatin, CGC-11047 and 5-flurouracil / leucovorin, CGC-11047 and sunitinib
- Drug
- Lead sponsor
- Progen Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2011
- U.S. locations
- 12
- States / cities
- Denver, Colorado • Ocoee, Florida • Indianapolis, Indiana + 9 more
- Conditions
- Type 2 Diabetes
- Interventions
- E3 Multidisciplinary Team, E3 Self-Guided Type 2 Diabetes Education
- Behavioral
- Lead sponsor
- Rush University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Lymphoblastic Leukemia, Pediatric
- Interventions
- Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 560 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2034
- U.S. locations
- 7
- States / cities
- Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
- Conditions
- Chronic Wounds, Biofilm Infection, Trans-epidermal Water Loss (TEWL), Diabetic Foot, Diabetic Foot Infection
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Tucson, Arizona • Cranberry Township, Pennsylvania
- Conditions
- Multiple Myeloma, Diffuse Large B-Cell Lymphoma, Glioblastoma Multiforme, Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Neuroendocrine Tumors of Non-Pancreatic Origin, Hormone Receptor-Positive Breast Cancer
- Interventions
- CC-223
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 10
- States / cities
- Los Angeles, California • San Francisco, California • Tampa, Florida + 6 more
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Azacitidine, IMGN632, Venetoclax
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 13
- States / cities
- Duarte, California • Orange, California • Tampa, Florida + 10 more